Soligenix Inc. Common Stock (SNGX)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham style investor, I start with business quality and survival. Soligenix is a 13-employee late-stage biopharma with two segments and a Phase 3 asset, SGX301/HyBryte, for cutaneous T-cell lymphoma. That is scientifically interesting, but not a proven commercial franchise. The filed numbers show fragility. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$2.0M and diluted EPS -$0.12. Fiscal Q1 2026, ended 2026-03-31, had net income -$2.8M and diluted EPS -$0.28. Fiscal Q3 2025, ended 2025-09-30, lost $2.5M, or -$0.58 per diluted share. Full-year FY2025, ended 2025-12-31, lost $11.1M, or -$2.14 per diluted share. FY2024, ended 2024-12-31, had revenue of $119,371 and a net loss of $8.3M; FY2023 revenue was $839,359 with a net loss of $6.1M. Revenue is negligible or unreported, while losses persist. FairStock's data at the 2026-10-13 close of $0.33 show P/B 1.06, P/E -0.46, ROE -241.65%, ROCE -84.87%, and FCF yield -150.1% on trailing FCF of -$10.8M. The Piotroski F-Score is 0/9 and Altman Z-Score is -48.49. Low D/E of 0.05 is a small comfort, but cash burn is enormous relative to the $7.2M market cap. There is no margin of safety I can measure. Until revenue and cash flow appear, this remains a speculative clinical-stage option, not a Graham-style bargain.

In plain English: Soligenix is a very small biotech company working on treatments for rare diseases. It has almost no sales, loses millions of dollars a year, and burns through cash. The low share price may look appealing, but the weak finances make it look speculative rather than a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer